Zhi Tong Cai Jing·2026-03-31 12:16Core Viewpoint - Shanghai Pharmaceuticals reported a revenue of 283.58 billion RMB for the fiscal year 2025, marking a year-on-year growth of 3.03%, with a notable increase in net profit attributed to a one-time special gain from accounting changes [2] Financial Performance - The pharmaceutical manufacturing segment generated sales of 24.52 billion RMB, reflecting a 3.33% increase year-on-year [2] - The pharmaceutical commercial segment achieved sales of 259.06 billion RMB, with a year-on-year growth of 3.00% [2] - Net profit attributable to shareholders reached 5.73 billion RMB, up 25.74% year-on-year, primarily due to a one-time special gain from changing accounting methods [2] - Adjusted net profit, excluding one-time items, was 4.72 billion RMB, representing a decline of 5.56% year-on-year [2] - The industrial segment contributed a profit of 2.04 billion RMB, while the commercial segment contributed 3.46 billion RMB [2] R&D and Innovation - The company successfully launched the innovative drug Apixaban, providing a new treatment option for over 300 million patients with primary hypertension, marking a significant achievement in its innovation efforts [3] - The global innovative anti-CD20 antibody drug B001 has completed key endpoint analysis in clinical studies [3] - The company is advancing several drugs in clinical trials, including SHPL-49 for acute ischemic stroke and SRD4610 for amyotrophic lateral sclerosis [3] - The company is enhancing its innovation ecosystem by integrating resources from academia, research, and industry, and is building a collaborative research management system [3] - The establishment of "One Hospital and Four Institutes" aims to strengthen internal technology platforms and foster external collaborations with leading research institutions [3]